Education
About Us
Working with TipRanks
Follow Us
111 Inc (YI)
NASDAQ:YI
Top Page
111
(NASDAQ:YI)
41Neutral
111 (YI) vs. S&P 500 (SPY)
Market Cap
$84.12M
Dividend YieldN/A
Average Volume (3M)37.07K
Price to Earnings (P/E)―
Beta (1Y)0.23
Revenue Growth-4.23%
EPS Growth16.52%
CountryUS
Employees1,520
SectorHealthcare
Sector Strength74
IndustryMedical Distributors
Share Statistics
EPS (TTM)-4.15
Shares Outstanding4,966,432
10 Day Avg. Volume43,955
30 Day Avg. Volume37,072
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.05
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
111 Business Overview & Revenue Model
Company Description111, Inc. (YI) is a leading online healthcare platform in China, operating a digital pharmacy and healthcare services marketplace. The company focuses on transforming the healthcare industry through its comprehensive online-to-offline (O2O) service model, offering users access to pharmaceutical products, medical consultations, and wellness services. By leveraging technology and a robust supply chain, 111 aims to improve healthcare accessibility and efficiency for consumers and businesses alike.
How the Company Makes Money111, Inc. generates revenue primarily through its online pharmacy sales, which include prescription and over-the-counter drugs. The company also earns through its online healthcare services, providing medical consultations and related digital health offerings. Additionally, 111 partners with pharmaceutical companies and healthcare providers to facilitate product distribution and enhance its service offerings. Key revenue streams include sales commissions, service fees, and strategic partnerships that leverage its digital platform to drive business growth.
111 Financial Statement Overview
Summary
The financial performance is weak, with declining revenue growth and persistent negative net income. The balance sheet indicates high financial risk with negative equity, and while cash flow has improved, it is not enough to offset the operational inefficiencies and financial instability.Income Statement
The company has experienced declining revenue growth, from 48.9% in 2020 to 8.2% in 2021, and further to 9.1% in 2022. The gross profit margin has been decreasing, and the net income remains negative, indicating ongoing struggles with profitability. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies.35
Negative
Balance Sheet
The balance sheet shows a concerning trend with negative stockholders' equity, indicating potential financial instability. The debt-to-equity ratio is not meaningful due to negative equity. The equity ratio is negative, highlighting high leverage. These factors suggest financial vulnerability and risk.25
Negative
Cash Flow
The company has improved its free cash flow from -$704 million in 2021 to $104 million TTM, indicating better cash management. However, the operating cash flow to net income ratio shows inconsistencies, and free cash flow to net income remains concerning due to negative net income.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 14.66B | 14.95B | 13.52B | 12.43B | 8.20B | 3.95B | Gross Profit |
| 651.61M | 448.44M | 839.98M | 621.10M | 365.83M | 165.18M | EBIT |
| -197.10M | -350.10M | -371.00M | -642.14M | -473.31M | -493.51M | EBITDA |
| -181.40M | -311.26M | -330.18M | -614.92M | -459.29M | -481.85M | Net Income Common Stockholders |
| -255.27M | -392.69M | -408.50M | -662.97M | -459.04M | -492.39M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 653.67M | 653.67M | 879.53M | 843.95M | 1.49B | 613.75M | Total Assets |
| 3.09B | 3.09B | 3.47B | 3.15B | 3.03B | 1.61B | Total Debt |
| 443.23M | 443.23M | 279.46M | 425.27M | 291.64M | 152.09M | Net Debt |
| -160.29M | -160.29M | -394.21M | -236.12M | -897.98M | -461.65M | Total Liabilities |
| 2.81B | 2.81B | 2.83B | 2.30B | 1.70B | 836.37M | Stockholders Equity |
| -583.45M | -583.45M | -414.60M | -173.32M | 357.40M | 776.66M |
| Cash Flow | Free Cash Flow | ||||
| 104.73M | -457.07M | -54.73M | -704.63M | -142.28M | -534.80M | Operating Cash Flow |
| 114.55M | -447.24M | -23.15M | -641.94M | -116.78M | -510.19M | Investing Cash Flow |
| 59.69M | 151.74M | -47.17M | 60.14M | -324.67M | 237.53M | Financing Cash Flow |
| -368.70M | 205.98M | 22.73M | 27.44M | 1.07B | 106.95M |
111 Technical Analysis
Positive
10.49
Price Trends
7.19
Positive
7.20
Positive
8.33
Positive
Market Momentum
0.74
Negative
68.39
Neutral
83.74
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For YI, the sentiment is Positive. The current price of 10.49 is above the 20-day moving average (MA) of 8.92, above the 50-day MA of 7.19, and above the 200-day MA of 8.33, indicating a bullish trend. The MACD of 0.74 indicates Negative momentum. The RSI at 68.39 is Neutral, neither overbought nor oversold. The STOCH value of 83.74 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for YI.
111 Risk Analysis
111 disclosed 83 risk factors in its most recent earnings report. 111 reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
111 Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | $2.07T | 35.53 | 24.29% | ― | 10.99% | 91.61% | |
71 Outperform | $82.90B | 100.14 | 6.27% | 2.05% | 6.84% | -17.14% | |
64 Neutral | $7.02B | ― | -4.31% | ― | 9.84% | 74.75% | |
54 Neutral | $2.92B | 122.36 | 2.97% | ― | 9.68% | ― | |
49 Neutral | $6.95B | 0.65 | -53.57% | 2.47% | 21.51% | 0.74% | |
41 Neutral | $84.12M | ― | 40.55% | ― | -4.23% | 16.52% | |
38 Underperform | $425.55M | ― | 81.52% | ― | -7.44% | 0.63% |
* Healthcare Sector Average
Performance Comparison
YI
111
10.49
-0.41
-3.76%
VNET
VNET Group, Inc. Sponsored ADR
8.71
6.91
383.89%
AMZN
Amazon
196.21
16.50
9.18%
EQIX
Equinix
834.59
58.10
7.48%
GDS
GDS Holdings
27.67
19.30
230.59%
RXT
Rackspace Technology
1.87
0.36
23.84%
111 Earnings Call Summary
Earnings Call Date: Mar 20, 2025 | % Change Since: -4.64% | Next Earnings Date: May 22, 2025
Earnings Call Sentiment Positive
The earnings call demonstrates significant achievements in operational profitability and cost reduction despite challenging macroeconomic conditions and regulatory changes. The company's advancements in technology and supply chain expansion position it well for future growth, though market and competitive pressures remain.Highlights
First Ever Operational Profitability
111 achieved its first ever operational profitability and positive operating cash flow in 2024, marking a significant milestone in the company's history.
Reduction in Operating Expenses
Total operating expenses decreased by 50.1% to RMB209.8 million in Q4 and by 31% for the full year, highlighting significant improvements in operational efficiency.
Advanced AI and Digital Capabilities
The company integrated leading technologies across operations, improving efficiency with AI-driven solutions and a fully digitized operating system.
Expansion of Fulfillment Centers
111 expanded its supply chain infrastructure with seven new fulfillment centers, increasing delivery efficiency and reducing costs.
Market Leadership and Industry Recognition
111 received multiple industry recognitions, including being named the most valuable healthcare and pharmaceutical company for investment.
Lowlights
Macroeconomic Challenges in China
Economic uncertainties and healthcare reforms in China have led to cautious consumer behavior, affecting retail sales and healthcare expenditure growth.
Decline in Retail Pharmacy Sales
Total retail pharmacy sales in China dropped by 2.2% in 2024 due to aggressive expansion during the pandemic and increased competition.
Challenges from Regulatory Changes
Ongoing healthcare reforms present short-term challenges as pharmacies adapt to new policies and regulatory frameworks.
Fulfillment Expense Increase
Fulfillment expenses rose slightly as a percentage of revenues due to a one-time warehouse relocation fee.
Company Guidance
During the conference call held on March 20, 2025, the management of 111 provided insights into their fiscal year 2024 performance and future outlook. Despite macroeconomic challenges and healthcare reforms impacting the industry, 111 achieved its first-ever operational profitability and positive operating cash flow. The company reduced operating expenses by 31% year-over-year, bringing them down to 5.7% of revenues. Key financial highlights included a yearly profit from operations of RMB2.1 million, a turnaround from a RMB350.1 million operational loss in 2023, and a non-GAAP income from operations of RMB22.3 million. The company also highlighted advancements in technology and supply chain infrastructure, such as their decentralized inventory network and AI-driven demand forecasting, which significantly improved operational efficiency. Looking ahead, 111 plans to leverage AI and digital transformation to enhance customer engagement and operational efficiency, aiming to capitalize on China's evolving healthcare market and structural trends like the aging population and healthcare transparency reforms.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.